Day TwoWednesday, 30 April 2025 - GMT (Greenwich Mean Time, GMTZ)

As the biotech and pharma industries face growing challenges in drug discovery—from rising R&D costs to complex disease targets— AI is reshaping what’s possible. Partnerships that leverage AI bring new opportunities to accelerate discovery timelines, increase the precision of drug candidate selection, and lower failure rates in clinical trials. This panel brings together experts in biotech, AI development, and pharmaceutical research to explore how strategic AI partnerships are paving the way for transformative advancements in drug discovery, improving both the speed and success rate of bringing life-saving drugs to market.

• Exploring key considerations and frameworks for forming successful AI partnerships, including aligning goals, handling data privacy, and fostering agile workflows.
• Discussing how AI-driven approaches, like deep learning and predictive modeling, are identifying novel targets, optimizing drug compounds, and accelerating preclinical and clinical phases.
• Addressing the ethical implications, regulatory hurdles, and need for transparency in AI-driven drug discovery to gain stakeholder and public trust

• Introductions by Moderator (2 mins)
  • The importance of licensing in fostering biotech growth and innovation
• Opening Presentation (15 mins)
  • Overview of Licensing in Biotech
    • Current trends and statistics in biotech licensing deals
    • Impact of recent high-profile licensing agreements on the industry
  • Importance of Licensing for Biotechs
    • How licensing can provide biotechs with access to new technologies, funding, and markets
    • Strategies for biotechs to position their intellectual property for successful licensing deals
  • Key Considerations for Successful Licensing Agreements
    • Essential elements of due diligence in licensing negotiations, valuation methods, and metrics
    • Importance of partnership alignment, ensuring mutual benefit, and managing expectations

• Introduction to the Case Study
  • Presentation of a successful biotech licensing deal and its impact on both parties
• Fireside Chat Questions:
  • Motivation Behind the Licensing Agreement
    • What drove the decision to pursue the licensing deal? What factors were considered?
  • Process Overview
    • Steps taken from initial IP identification and valuation to the signing of the licensing agreement, including challenges encountered and how they were addressed
  • Outcome and Lessons Learned
    • Key insights gained from the process and the impact of the licensing deal on the biotech's growth
  • Future Considerations
    • What to expect in future licensing activities based on current market trends and evolving technology

• Open Floor for Questions (10 mins)
  • How should biotech companies prepare their IP for licensing discussions?
  • What specific attributes do potential licensees look for in a biotech company’s portfolio?
  • How can licensing be used strategically to drive growth and innovation in biotech?
• Wrap-Up Discussion (5 mins)
  • Summarize key takeaways from the workshop
  • Highlight actionable insights for biotech companies considering licensing opportunities